Advertisement
Screener

MaxCyte, Inc. (MXCT) Overview

MaxCyte, Inc. (MXCT) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.08; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.04; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.12; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.12; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$0.65$0.80$0.98$1.21$1.50$1.852025-11-062026-11-06$0.65$1.19$2.18$4.02$7.39$13.592021-11-082026-11-06$0.65$1.26$2.45$4.77$9.28$18.062021-07-302026-11-06$0.65$1.26$2.45$4.77$9.28$18.062021-07-302026-11-06$0.65$1.26$2.45$4.77$9.28$18.062021-07-302026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$1.25
Previous close
$1.18
Change
$0.07
Change (%)
5.93%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

MXCT
-23.87%
S&P 500
(m)

1 year

MXCT
-21.33%
S&P 500
(m)

3 years

MXCT
-62.18%
S&P 500
(m)

5 years

MXCT
-90.41%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.08

-0.20-0.12-0.030.050.1431 Mar 2025: estimate (m); actual -0.1031 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.1230 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.1230 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.0431 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.0830 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.08(m)(m)
1 Jan 202631 Mar 2026(m)-0.04(m)(m)
1 Jul 202530 Sept 2025(m)-0.12(m)(m)
1 Apr 202530 Jun 2025(m)-0.12(m)(m)
1 Jan 202531 Mar 2025(m)-0.10(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -0.42

-0.50-0.38-0.27-0.15-0.0331 Dec 2021: estimate (m); actual -0.2131 Dec 2021(m)31 Dec 2022: estimate (m); actual -0.2331 Dec 2022(m)31 Dec 2023: estimate (m); actual -0.3731 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.3931 Dec 2024(m)31 Dec 2025: estimate (m); actual -0.4231 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-0.42(m)(m)
1 Jan 202431 Dec 2024(m)-0.39(m)(m)
1 Jan 202331 Dec 2023(m)-0.37(m)(m)
1 Jan 202231 Dec 2022(m)-0.23(m)(m)
1 Jan 202131 Dec 2021(m)-0.21(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 4.94M ■ Earnings -8.87M — Profit margin -179.78%

-14.50M-270.7%-7.33M-215.3%-0.15M-159.9%7.02M-104.5%30 Sept 2025: revenue 4.60M; earnings -12.42M; profit margin -269.74%30 Sept 202531 Dec 2025: revenue 4.79M*; earnings -9.60M*; profit margin -200.46%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 4.50M; earnings -4.75M; profit margin -105.53%31 Mar 202630 Jun 2026: revenue 4.94M; earnings -8.87M; profit margin -179.78%30 Jun 2026

31 Dec 2025 ■ Revenue 20.96M ■ Earnings -44.63M — Profit margin -212.96%

-53.44M-214.0%-23.11M-169.6%7.22M-125.3%37.55M-81.0%31 Dec 2022: revenue 28.75M; earnings -23.57M; profit margin -81.99%31 Dec 202231 Dec 2023: revenue 19.50M; earnings -37.92M; profit margin -194.51%31 Dec 202331 Dec 2024: revenue 22.21M; earnings -41.05M; profit margin -184.81%31 Dec 202431 Dec 2025: revenue 20.96M; earnings -44.63M; profit margin -212.96%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$1.25(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$1.25High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning MXCT

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Index membership
(m)
Employees
114.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
384.49K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-4.84%*
Total return · month
-3.28%*
Total return · quarter
-4.84%*
Total return · half year
73.53%*
Total return · year to date
-23.87%*
Total return · 1 year
-21.33%*
Total return · 3 years
-62.18%*
Total return · 5 years
-90.41%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

MaxCyte, Inc. Overview

View more →

(m)

(m)

SEC CIK
1287098
Industry (SIC)
8731 Services-Commercial Physical & Biological Research
Country of operation
United States
Business address
9713 KEY WEST AVENUE,, SUITE 400, ROCKVILLE, Maryland, 20850, United States
Fiscal year end
1231
Phone
301-517-5556

Similar stocks

Stock NameCountryMarket CapPE Ratio
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71
NRC HEALTH (NRC)United States$0.450B42.50
OmniAb, Inc. (OABI)United States$0.698B-8.05
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14